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Abstract
Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more than 320 million people worldwide, which is more than 
HIV, tuberculosis (tB) and malaria combined. elimination of HBV and HCV will, therefore, produce substantial public 
health and economic benefits and, most importantly, the prevention of 1.2 million deaths per year. In 2016, member 
states of the World Health Assembly unanimously adopted a resolution declaring that viral hepatitis should be eliminated 
by 2030. Currently, few countries have elimination programmes in place and even though the tools to achieve elimination 
are available, the right resources, commitments and allocations are lacking. During the fifth International Viral Hepatitis 
elimination Meeting (IVHeM), 7–8 December 2018, Amsterdam, the netherlands, an expert panel of clinicians, virologists 
and public health specialists discussed the current status of viral hepatitis elimination programmes across multiple 
countries, challenges in achieving elimination and the core indicators for monitoring progress, approaches that have 
failed and successful elimination plans.
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Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) affect more 
than 320 million people worldwide, which is more than HIV, 
tuberculosis (tB) and malaria combined [1,2]. elimination of 
HBV and HCV will, therefore, produce substantial health and 
economic benefits and, most importantly, the prevention of over 
1.2 million deaths annually [1].
In 2016, the World Health Assembly (WHA) unanimously adopted 
the resolution that viral hepatitis should be eliminated by 2030. 
In addition, the World Health organization (WHo) published the 
Global Health Sector Strategy on hepatitis to reach this goal [1]. 
the International task force for Disease eradication (ItfDe) 
adapted and endorsed the elimination goals of WHo, and HBV 
and HCV infections are recognised as feasible targets for elimina-
tion. In addition, WHo established a framework to guide imple-
mentation of the key interventions at a national level to achieve 
the global elimination goals. At the start of the elimination era 
for viral hepatitis, few countries are on track to meet the 2030 
elimination goals. Moreover, in 2017, only 28% and 48% of 
countries are reported to have elimination plans in place for HBV 
and HCV, respectively [3,4].
HBV and HCV infection meet accepted criteria for disease elimi-
nation. However, appropriate resources, commitment and allocation 
are currently lacking. If the right parties work together, including 
governments, international organisations, the private sector and 
civil society, great success can be achieved. Modelling studies 
have indicated that if core interventions are implemented with 
sufficient service coverage, elimination could be accomplished. 
this will require collecting strategic information, planning of 
programmes with involvement of all stakeholders, engaging civil 
society, arranging financial support and implementing appropriate 
strategies for target populations [5]. Key for the viral hepatitis 
response is to be integrated within countries’ efforts to achieve 
universal health coverage as part of the 2030 Sustainable Devel-
opment Goals.
During the fifth International Viral Hepatitis elimination Meeting 
(IVHeM), 7–8 December 2018, Amsterdam, the netherlands, an 
expert panel of clinicians, virologists and public health special-
ists discussed what progress is needed to achieve elimination, 
what major challenges are still to be faced and, in addition, the 
core indicators for monitoring progress. IVHeM brought together 
current or proposed HBV and HCV prevention and elimination 
programmes to share local experiences in planning and implemen-
tation of the key interventions recommended by WHo. through 
information sharing, the goals of the meeting were to help pro-
grammes improve performance and guide development of new 
elimination programmes.
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The investment challenges
A major barrier towards elimination is the lack of funding. Viral 
hepatitis is significantly underfunded compared to HIV, tB and 
malaria. Currently, there is no significant support from the Global 
fund, pepfAr, the Gates foundation or other similar international 
funders outside of the setting of HIV co-infection. Without some 
support from these, or similar organisations it is unlikely that the 
2030 elimination targets will be achieved [4].
Several reasons have been postulated as to the lack of funding 
for viral hepatitis. first, there is limited knowledge about the 
high cost of the viral hepatitis epidemic that will continue to 
grow in future years if current trends in testing and treatment 
continue. reaching the 2030 elimination targets by increas-
ing testing and treatment can, however, stop these increasing 
costs. In fact, achieving viral hepatitis elimination will produce 
a positive return on investment by 2028 from savings due 
to the removal of indirect cost associated with viral hepatitis 
[4]. Additionally, some countries are likely to obtain an even 
greater health benefit with their current investment. egypt 
for instance is currently undertaking massive screening pro-
grammes for HCV, but has built into this screening for multi-
ple diseases including HBV, obesity, diabetes and hypertension. 
In the first 20 days in october, over 4 million people were 
screened with 140,000 HCV cases detected; as well as more 
than 1 million cases of obesity and 20,000 diabetic patients were 
identified.
A second likely reason for the lack of investment is that, viral 
hepatitis infects many minorities who are often highly vulnerable 
and underrepresented at a political level. Due to their vulnerability 
these groups are often not in position to advocate for support 
and funding. HIV is an example where involvement of civil society 
drove the HIV movement and resulted in awareness, political 
support and funding. Work needs to be done to support civil 
society and community organisations to be engaged and advo-
cating for funding. only with enough community advocacy will 
the political leadership start to support the matter and the pledge 
for a global fund can begin.
Whilst the viral hepatitis response would benefit from the support 
of international funding organisations, it is key that individual 
countries take responsibility for supporting the investment in 
elimination. China is a good example. Sustainable HBV pro-
grammes were established with support from private partnerships 
and leadership [4]. GAVI was one of the organisations that sup-
ported universal hepatitis B immunisation of infants in China. In 
addition, organisations such as GAVI, which recently announced 
prioritised investment in HBV birth-dose vaccines, can make a 
tremendous difference with raising awareness particularly through 
immunisation campaigns, especially in low- and middle-income 
countries. Georgia’s HCV response is another example where a 
strong government leadership, combined with private investment 
from Gilead Sciences and technical support from the US Centers 
for Disease Control and prevention and fInD/Unitaid led to 
successes.
the lack of national and international investment in viral hepatitis 
programmes, especially in low- and middle-income countries, 
means that national hepatitis programmes are underfunded. As 
a result, testing programmes are hampered and only small numbers 
of individuals therefore have access to treatment [6]. In order to 
establish a strong hepatitis response and strengthen healthcare 
systems, especially in low- and middle-income countries, financial 
support is needed to lay the groundwork for elimination by pro-
viding essential research and support [6].
Strategic information of successful countries on 
track towards the elimination goals
there are several countries that have developed elimination plans 
[3,4]. one of the most successful countries is egypt, where many 
are already cured, and mass testing programmes are identifying 
the millions of individuals who are unaware of their infection [7]. 
not only adults are included in these programmes: egypt is also 
including children and adolescents. By testing and treating the 
young population, parents are also engaged in testing. In addi-
tion, adolescents tend to strengthen the community by raising 
awareness and advocacy. During the testing programme, stigma 
in schools or when parents where asked for consent for testing 
of their child has been identified. By working together with 
organisations such as the national mother and child organisation, 
knowledge is gained regarding the protection of children from 
discrimination and stigma. this approach can be an example for 
other countries, since worldwide over 11 million children (under 
the age of 15) have HCV infection [8].
Georgia is another country that has successes in eliminating viral 
hepatitis. there is a high prevalence of HCV infection (5.4% of 
adults have HCV) [9]. Since 2015, an HCV elimination programme 
has been in place, based on six main principles: (1) advocacy, 
awareness and education, and partnerships for HCV-associated 
resources; (2) HCV transmission reduction; (3) identification of 
those with HCV; (4) HCV laboratory diagnostics; (5) HCV care 
and treatment; and (6) HCV surveillance. the programme receives 
funding from the Global fund, and is constantly evolving to meet 
the beneficiaries’ needs. Georgia uses an integrated approach by 
combining testing protocols and care for HIV, tB and HCV. By 
integrating viral hepatitis care into existing platforms, costs are 
reduced. to improve coverage and maximise the number of the 
target population, Georgia decentralises HCV-related services. 
this improves accessibility for persons living in rural areas. In 
addition, primary healthcare workers and non-specialised settings 
near patients’ homes are involved in the management of uncom-
plicated HCV cases.
Iceland is also leading in elimination and, according to mathematical 
models, could potentially reach the WHo elimination targets by 
2020 [10]. A nationwide programme has been established, treat-
ment as prevention for Hepatitis C (trap HepC), where universal 
access to direct-acting antivirals (DAAs) is combined with intensi-
fied screening and harm-reduction efforts. one central virology 
laboratory serves the entire country and reports all new HCV 
infections directly to a national HCV registry. emphasis is on early 
case finding and treatment of high-risk groups such as persons 
who inject drugs (pWID) and prisoners, as well as patients with 
advanced liver disease. Using the treatment-as-prevention (tasp) 
approach, previously described as a good tool for HIV prevention 
and described as effective for HCV, the aim is to not only offer a 
cure to patients but also to reduce the domestic HCV incidence 
by 80% prior to the WHo elimination goals for 2030 [11–13]. 
the programme has already resulted in a major decrease of HCV 
prevalence among key risk groups such as pWID and prisoners.
In Athens (Greece), a fast-track intervention to seek-test-link-
treat pWIDs has been established, based on a programme estab-
lished during an outbreak of HIV among persons who inject drugs 
[14,15]. Athens accounts for 8700 high-risk drug users, of whom 
2450 had actively injected in the past 30 days [16]. Harm-
reduction programmes with opioid substitution therapy (oSt) 
and needle syringe programmes (nSp) are in place, but waiting 
times are long. In addition, DAAs have been available without 
restriction since September 2018. However, they are only accessed 
by a small percentage of pWIDs. the current programme is used 
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to increase diagnosis and treatment for HCV and HIV infection 
among pWIDs. Chain-referral sampling is used to bring individuals 
into care (a single individual from a target population is invited 
and requested to invite three other recruits from their network) 
[17]. A combination of rapid identification, fibroscans and bio-
chemical testing are used in a single visit to avoid losing individuals 
in the care cascade (table 1). Specially trained clinicians visit the 
study site, to improve linkage to care. In addition, pWIDs are 
assigned a peer-navigator, who accompanies them to their first 
liver or infectious diseases clinic appointment. Similarly to Iceland, 
a national HCV treatment registry is used to monitor progress 
and to improve linkage to care.
In the United States the Veterans Administration (VA) uses Lean 
as a strategic methodology to improve HCV care (table 1). Lean 
is a business methodology that promotes the flow of value (care) 
to the customer (patient), through continuous improvement, and 
increases access to information to ensure responsible decision-
making. Currently, 8.9 million veterans receive VA care, and the VA 
leadership has identified HCV as a priority. ‘Hepatitis Innovation 
Table 1. the challenges, failures, lessons learned and solutions from different countries in efforts to eliminate viral hepatitis
Country Challenge and/or failures Solutions and lessons learned
egypt High HCV prevalence, treated all patients and 
screening programmes were running behind, cost 
of diagnosis, number of pCr tests was a 
bottleneck
 • Before 2014: established data networking centre and political will to eliminate 
HCV. Since, 2016 pledge from the president to eliminate HCV [7]
 • national plan since 2014 including HCV treatment centres
 • Generic DAAs
 • Decentralising the screening project by using mobile units and different 
testing sites
 • negotiated for a lower pCr price given number fo tests required
 • Loan from the World Bank and private sector cooperation
 • Companies helped to develop dried blood spot test
 • Simplify the monitoring strategy
Georgia High HCV prevalence, need to identify the 
missing millions, reaching the younger 
population, cost, linkage to care
 • Integrated hepatitis care into HIV, tB and malaria care
 • Scaling-up advocacy for hepatitis, HIV and tB
 • Decentralisation of healthcare (screening and treatment) using primary 
healthcare
 • Massive screening programmes, focusing on affected age group of males 
(30–60 years) and high-risk groups
 • Universal screening in harm-reduction networks
 • Used medical university students as extra help in these harm-reduction 
networks
 • When elimination was feasible the authorities were on board
 • Strengthen the healthcare system through the support of Global fund
 • More enrolment of public health specialists for linkage-to-care process
Australia reaching the younger population, decline in 
number of people accessing treatment [18]
 • Decentralising care and bringing care to the community where patients access 
services (community care/primary care) [19]
 • point-of-care test in needle and syringe programmes (rApID-eC)
 • Increase awareness about new HCV treatments
 • Increase coordination between services, for example community and prisons
 • Support enhanced data management
france prioritisation of treatment, high drug cost, high 
HCV prevalence and HCV transmission among 
pWIDs [20]
 • established mathematical models to gain further insight into the best 
treatment strategies and harm-reduction programmes [21–23]
 • price negotiations allowing the significant decrease in drug costs
United States High HCV prevalence, optimising HCV in the VA  • System redesign using LeAn methodology [26,27]
netherlands Linkage to care of the high-risk group, retention 
in care
 • Involving target group in establishing linkage-to-care strategies
 • Using affected community in building online and offline information platform 
[28]
 • Development of play-safe chemsex toolkit 
Canada projects stalled due to constant data gathering 
required by health authorities, screening 
programmes were successful but the labs could 
not process the numbers
 • not everything has to be perfect
 • negotiating is power, important to get all the major players in the room. the 
leadership must push the agenda forward; in addition, the industry must also 
understand the needs and can support the gaps in care
Myanmar Low general awareness and in key populations, 
rural areas hard to reach, low vaccine coverage
 • Aiming for high advocacy by increasing the political will
 • Decentralisation of healthcare
rwanda receiving funding  • Government acknowledged viral hepatitis as a major health problem and 
sought funding
 • Strengthening of the programme by the Global fund 
Greece Small numbers of pWIDs accessed care, waiting 
lists for harm-reduction programmes are long
 • established a fast-track intervention to seek-test-link-treat pWIDs [14,15]
 • Used previous HIV programmes as an example
 • Chain-referral sampling to engage individuals into care [17]
 • rapid identification, fibroscans and biochemical testing all in a single visit
 • peer-navigators to improve linkage to care 
Iceland Some actively injecting drug users remain 
difficult to engage in treatment and maintain on 
treatment; visitors from abroad, such as asylum 
seekers and foreign prisoners with pre-existing 
chronic HCV infections; patients at an increased 
risk of infection and re-infection (MSM, persons 
sharing needles)
 • Incentives (including financial) for difficult patients. Adherence support
 • Screening of immigrants and asylum seekers. Collaboration with the chief 
epidemiologist and immigration authorities.
 • Scale-up of HCV testing and harm-reduction efforts, including increased 
access to needles and syringes (nSp)
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teams’ (HIt) were installed at each hospital, comprising doctors, 
pharmacists, nurse practitioners, physician assistants, research 
nurses, clerks and system redesign personnel. their aim is to 
improve HCV care by redesigning care and the delivery pro-
cesses with the lean methodology, which makes it feasible to 
measure improvements in variability, access, quality of HCV care 
and problems with HCV screening. each year, the HIt leadership 
teams set national goals for HCV testing rates and treatment 
rates. In addition, they have constructed HCV dashboards, where 
providers have clear ‘real-time’ access to patient data. Moreover, 
HIts established different testing interventions such as: clinical 
reminders; reflex HCV-rnA testing; performance indicators for 
healthcare executives; and multimedia marketing. Special pro-
grammes are focused on at-risk groups by educating and partnering 
with mental health and substance use treatment providers and 
homeless stand-downs. Challenges are that many of the remain-
ing untreated patients have barriers to receiving treatment, such 
as homelessness, substance use, refusal of treatment, other co-
morbidities (e.g. cancer), or do not use VA services at this time.
Gaps in the treatment cascade
finding the missing millions
Care-cascade analysis is an essential evaluation tool for the chal-
lenges on the way to cure. the cascade of care for HBV and HCV 
showed that one of the major difficulties on the road to elimina-
tion is finding the missing millions affected by the illnesses. While 
egypt was very successful in treating all known individuals with 
HBV and HCV, there were many who were undiagnosed and 
massive testing programmes were needed to identify the missing 
millions [7]. With major support from the president, successful 
negotiations with several companies saw reduced prices for in 
vitro diagnosis tests. By simplifying diagnostics and the costs of 
follow-up programmes, the cost for each case of HCV elimination 
declined. Subsequently, the lack of polymerase chain reaction 
machines created the next bottle neck, limiting the number of 
specimens that could be tested. to solve the capacity problem, 
a change to diagnosis and screening using point-of-care tests 
was made. this allowed decentralised testing using mobile units 
and local testing sites, tackling the issue region by region rather 
the whole country at once.
In rwanda, there is a strong political will to eliminate hepatitis, 
due to the higher mortality from viral hepatitis than from HIV. 
the rwandan government supported hepatitis elimination pro-
grammes by allocating $9 million and obtained support from the 
Global fund. HBV and HCV prevalence is estimated to vary around 
3.1–4.5% and 4.6–8.9%, respectively (total population of 12 
million) [29]. HIV programmes form a successful model for service 
delivery and platforms for testing (viral load and genotyping). 
therefore, hepatitis screening services have been successfully 
integrated into existing HIV care. In addition, DAAs are freely 
available. In rwanda, 280,000 individuals were tested, 9000 
patients were treated, and television and radio were used to 
target individuals aged 45 and older for hepatitis testing to reach 
the missing millions.
one major barrier in finding the missing millions is the lack of 
awareness of viral hepatitis. Globally, 9-out-of-10 individuals are 
unaware of their infection status, as most have no well-defined 
symptoms and many do not classify themselves as belonging to 
at-risk groups [1]. In addition, millions of people have been, and 
continue to be, infected, accidentally and unnoticed, by unscreened 
blood transfusions and unsterilised equipment [30]. Although 
certain countries have established massive testing programmes, 
there is still limited experience on how to engage with large 
numbers of undiagnosed individuals, and it is likely to vary between 
countries and regions depending on which risk behaviours are 
driving the epidemic.
A good insight into country-specific epidemics is essential as a 
baseline for the development of testing approaches. the HCV 
epidemic in Canada, for instance, is concentrated around birth 
cohorts and most people are unaware of their risk. targeted testing 
in birth cohorts, therefore, would be a perfect strategy, although 
this would be an insufficient strategy in egypt, where HCV exists 
among the whole population. Solely testing the birth cohort 
results in many undiagnosed infections, so screening programmes 
should be implemented more widely. By contrast, in Australia, 
former and current pWIDs are aware of their infection but unaware 
of the availability of curative DAAs. this does not require a testing 
programme but linkage to care. Mathematical models can help 
to identify the most cost-effective testing strategy [23].
Improving linkage to care
Linkage to care is crucial and an important precursor to retention. 
Cascade analysis with recent data is fundamental to improve 
linkage to care. As an example, in African countries, cascade 
analysis pointed to a more pronounced treatment gap compared 
to other regions [1,10,31]. A common reason for delaying health 
services among people living with HIV/AIDS was ‘medical plural-
ism’, the use of multiple health systems including traditional 
healers in sub-Saharan Africa [32,33]. Many lessons can be learned 
from HIV care, which can be used in determining viral hepatitis 
linkage-to-care programmes. In particular, viral hepatitis testing 
can be integrated into the already existing delivery models for 
HIV and primary care.
Several minorities also face linkage-to-care issues, often due to 
stigmatisation and low political commitment. this results in limited 
service penetration and a lack of engagement of healthcare pro-
viders. In the UK for example, homeless persons, are estimated 
to be 50 times more likely to have chronic HCV infection, but 
only 3% receive treatment [34]. pWIDs also have difficulties in 
finding health care, which is a significant barrier in linkage to 
care. there is also a lack of specialised services and programmes 
for younger people who would particularly benefit from earlier 
treatment and care. Currently, only egypt has a testing and treat-
ment programme for adolescents, and more countries should 
advocate for treatment programmes among this age group. Calling 
attention to marginalised populations is appropriate since HBV 
and HCV are often the result of poor healthcare and a problem 
for civil society as a whole. public education can build awareness 
of the burden of disease and linkage to liver cancer to promote 
greater advocacy by civil society to call on political leaders to 
commit national resources to HCV and HBV elimination.
In the netherlands, linkage to care for high-risk groups was one 
of the major challenges (table 1) and the community generated 
Box 1. essential components of HCV elimination programmes 
 • Data are used to assess HCV disease burden and health system 
capacity
 • plan of action with time limited numerical targets
 • Civic and political support for implementing partners and target 
populations
 • Capacity to deliver appropriate interventions to target 
populations
 • Sustainable models for financing programmes
 • Integration of services in existing health systems
 • Strategic data to monitor programme performance and progress 
towards elimination goals
 • participation in operational research
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innovative ideas. new HCV infections are concentrated among 
men who have sex with men (MSM) [35,36] while new cases of 
HCV among pWIDs are very low: in 2016 there were 44 cases 
in MSM with fewer than five associated with injection drug use 
[37]. Since 2015, DAAs have become available without restric-
tion, which resulted in a decline in incidence of 70% among 
MSM [11,38]. However, re-infections are still high and predomi-
nantly related to the involvement of MSM in high-risk sexual 
activities (including chemsex). MSM are, therefore, the key group 
for interventions. Currently, innovative harm-reduction strategies 
are used in close collaboration with the community to achieve 
HCV elimination. noMoreC is a good example of a community 
platform where MSM educate other MSM on HCV and safe sex. 
In addition, play-safe toolboxes can be ordered as well as free 
HCV home tests, based on dry bloodspot testing [28]. the aim 
of this platform is to increase awareness and knowledge, encour-
age regular and timely testing, and offer tailored advice to MSM 
to reduce their risk of acquiring HCV [28].
HCV treatment uptake in Australia was initially high, but has 
begun to fall over the past 12 months [39]. Several barriers for 
linkage to care were identified, such as: a shortage of healthcare 
practitioners in some area (particularly rural and regional Australia), 
lack of coverage services; stigma and discrimination; accessing 
tertiary care services; and HCV being not a priority [18] (table 1). 
As a solution, Australia redefined linkage to care models towards 
the community, where patient access to services and care was 
decentralised. Several studies, for example, the prIMe study and 
rApID-eC, showed that patients were more likely to engage in 
care when DAAs were given in primary care compared to tertiary 
hospitals [19,40]. prescribing rules were changed and, by 2018, 
most DAAs were prescribed by general practitioners.
HBV care is neglected compared to HCV
HBV care is ‘neglected’ compared to HCV in terms of treatment 
and, in addition, there is still limited recognition of the illness. 
there are several reasons why. first, the greatest HBV morbidity 
and mortality is found in low- and middle-income countries. In 
many of these countries HIV had been a major contributor to 
morbidity and mortality until the development of good coverage 
of antiretroviral therapy. Additionally, with the advent of DAAs, 
HCV has become a treatable condition; however, HBV has been 
left behind. Second, there is no community movement, as there 
was with HIV, to bring the condition into the spotlight. Civil 
society is very important for creating advocacy and raising aware-
ness. With the availability of DAAs, this awareness has increased 
for HCV, although mostly led by drug company treatment cam-
paigns rather than by the affected community. third, HBV testing 
needs to be more accessible and cost barriers need to be reduced. 
HBV monitoring is also difficult with many different steps. Addi-
tionally, the timely use of HBV vaccination at birth is a challenge 
in certain countries, particularly in sub-Saharan Africa where 
coverage is around 10%.
Monitoring progress
Monitoring progress is an important element in the elimination 
effort to ascertain if interventions, such as vaccination programmes 
and other prevention efforts are being effective, whether testing 
is increasing, and if those testing positive are being linked to 
care as necessary. Without monitoring, progress cannot be meas-
ured, and the impact of the epidemic cannot be understood. 
WHo recommend three elements for surveillance and 10 core 
indicators [30]. for surveillance: (1) enhanced case reporting of 
acute hepatitis describes incidence trends and identifies who 
acquire hepatitis; (2) biomarker surveys generate reliable popu-
lation-based estimates of the prevalence, preferably by age; and 
(3) sequelae surveillance captures mortality from viral statistics 
and the attributable fraction describes mortality trend [30]. 
Cascade monitoring relies on aggregated or individual data. If it 
is not possible to obtain new data, existing data can be extrapo-
lated to provide working estimates to allow the establishment of 
elimination programmes.
WHo plans to monitor progress towards elimination by requesting 
countries to report on their progress by core indicators [30]. 
WHo is to publish new simplified, consolidated guidelines on 
hepatitis strategic information that will propose a simplified 
approach for conducting rapid data extraction to report progress 
towards elimination in the Global reporting System for Hepatitis 
(GrSH) [30]. WHo will monitor what is new, policy uptake, cascade 
of care and sequelae. With this information, WHo will provide a 
global system of centralised data.
What further steps are needed
Hepatitis B vaccination of infants, blood safety programmes and 
universal precautions in healthcare settings have already greatly 
reduced HBV and HCV incidence. However, morbidity and mortal-
ity are still increasing. What is further needed is to prioritise the 
full implementation of timely HBV vaccinations, drug addiction 
therapies, safe injection equip ment and HCV treatment for persons 
who inject drugs, and assured access to testing, care and treat-
ment for those with HBV and HCV.
In addition, countries should establish elimination programmes 
with action plans that have time-limited numerical targets and the 
capacity to deliver appropriate interventions to target populations, 
with egypt and Australia as good examples. Moreover, services 
should be integrated in existing health systems, as successfully 
achieved in Georgia, and strategic data should be used to monitor 
programme performance and progress towards elimination goals 
with Iceland and the VA as examples. Countries should also par-
ticipate more in operational research.
furthermore, a global coalition, as recommended by the ItfDe, 
can help by building the capacity and advocacy towards elimina-
tion [41]. Large elimination campaigns are often supported by 
coalitions of implementing programmes, funding organisations, 
technical experts, and even international organisations such as 
WHo. A global coalition, guided by the ItfDe and experiences 
of other elimination programmes can provide the knowledge and 
experience, and can establish dynamic evidence-based meetings 
such as IVHeM, which can provide assistance from technical 
experts and opportunities for generating new knowledge.
Conclusion
During IVHeM, key elements, such as linkage to care, finding the 
missing millions, awareness, stigma, cost, and lack of funding were 
discussed as challenges to elimination programmes. the experience 
gained from previous and current disease elimination initiatives 
revealed the essential components of effective elimination pro-
grammes, including action plans, building capacity, integrated 
services, collecting strategic data, and monitoring progress.
examples from several countries were given on how costs were 
lowered and existing healthcare systems were used. for example, 
the VA fully integrated HBV and HCV care into existing services 
and Georgia integrated and decentralised towards primary care. 
other methods for lowering costs were discussed, such as in 
egypt, where negotiations with companies reduced the cost of 
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testing due to the large volume required and generic DAAs were 
manufactured locally. In addition, Australia more affordable inter-
ventions and diagnostics were negotiated and primary care services 
are being used to deliver treatment.
In order to establish elimination, collection of strategic informa-
tion, involvement of all stakeholders, engagement with civil society, 
and arrangement of financial support were considered important 
elements. Iceland was given as a good example of where public 
and private partnership, in combination with a HCV registry, led 
to a successful nationwide elimination programme.
to improve linkage to care, appropriate strategies for the target 
population should be established as for example in the netherlands 
where the community was engaged in creating a programme.
Most importantly, in order to achieve elimination, we need more 
involvement from the community, and bring the right parties 
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